Semaglutide D
DrugTablet given orally
NCT Number: NCT05129891
In this study, four new tablet versions of two compounds will be investigated.
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet versions. The tablet versions, participants will receive, i.e. the treatment arm participants will be assigned to, is decided by chance.
Participants will receive one treatment for 10 days in the first period. For the second period, directly following, participants will receive a different treatment for five more days.
The study can last for up to approximately 10 weeks for each participant. This includes a screening period (up to 3 weeks), two treatment periods (together a total of 15 days) and a follow-up visit (5 weeks after the last dosing)
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Altasciences Company Inc., Montreal, Quebec, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Tablet given orally
Time frame: From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration
h * nmol/L
Time frame: From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration
nmol/L
Time frame: From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration
hours
Novo Nordisk A/S
Industry
A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05521256
Diabetes Mellitus, Diabetes Mellitus, Type 2
Neuss, North Rhine-Westphalia, Germany
View Trial DetailsNCT05227196
Diabetes Mellitus, Diabetes Mellitus, Type 2
Cypress, California, United States
View Trial DetailsNCT04676906
Diabetes Mellitus, Diabetes Mellitus, Type 2
Groningen, Netherlands
View Trial DetailsNCT04097600
Diabetes Mellitus, Diabetes Mellitus, Type 2
Berlin, Germany
View Trial Details